IP Verse

Rapid Dissolution Formulation Of Cinacalcet Hcl

EP3395338

AMGEN
Application Number
EP18175495A
Filing Date
Sep 10, 2004
Status
Revoked
Apr 29, 2022
Grant Date
May 1, 2019
External Links
Slate, Register

Biblio Summary

The patent EP3395338B1 was granted on May 1, 2019 by Amgen The patent is currently Revoked.

Oppositions Filed by other Companies on the Patent

The table below shows 7 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

BETAPHARM ARZNEIMITTEL GMBHDec 9, 2020INTERVENTION ADMISSIBLE
AECHTER, BERNDJan 31, 2020ADMISSIBLE
BIOGARANJan 31, 2020ADMISSIBLE
HGF LIMITEDJan 31, 2020ADMISSIBLE
ACCORD HEALTHCARE LTDJan 31, 2020WITHDRAWN
GLENMARK PHARMACEUTICALS EUROPE LTDJan 27, 2020ADMISSIBLE
TEVAJan 13, 2020WITHDRAWN

More Opposed Patents of Amgen

The table below shows the patents of Amgen that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP4209499Charged Depth Filtration Of Antigen-Binding ProteinsAug 7, 20241
EP3819007Dosing Regimen For Anti-Bcma AgentsJul 10, 20244
EP2637670Prevention Of Adverse Effects Caused By Cd3 Specific Binding DomainsMar 13, 20244

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.

  • Date

    Description

  • Get instant alerts for new documents